NEWS

• Expert modelling points to a more severe influenza season than in previous years.1
• The lifting of restrictions to reduce COVID-19 transmission may leave vulnerable people – with reduced immunity - at greater risk from influenza.1
• Co-administration of the seasonal influenza vaccine with the COVID-19 booster may not only protect vulnerable populations, it could also relieve the burden on healthcare systems.
• A panel of leading international experts discuss the challenges of the oncoming influenza season at this year’s EU Flu Day, led by Vaccines Europe and supported by Seqirus.

• Seqirus will develop and evaluate two influenza A(H2Nx) virus vaccine candidates in support of U.S. government pandemic preparedness objectives
• Company will utilize its combination of cell-based and adjuvanted influenza vaccine technologies, as well as its next-generation self-amplifying mRNA platform
• Multi-year contract with Biomedical Advanced Research and Development Authority (BARDA) builds on longstanding, successful public-private partnership to provide rapid vaccine manufacturing response in an influenza pandemic

• Appoints Roberta Duncan as new program lead to drive technology advancement
• Accelerates development of sa-mRNA vaccine candidates for seasonal and pandemic influenza

The company is prepared to meet the record levels of demand seen during the 2020/21 influenza season amidst the ongoing COVID-19 pandemic.

First doses of Seqirus’s enhanced influenza vaccine, destined for the U.K., come off a new high-speed fill-and-finish line in Liverpool.

This news release is intended for Health Professional media only.

Forbes Recognizes Global Biotechnology Leader for Fourth Straight Year

The first annual EU Flu Day was launched today, 14 October 2020. Marking the occasion, Seqirus, a global leader in influenza prevention, announced that it has delivered shipments of influenza vaccines on schedule, across Europe

CSL Limited (ASX:CSL) today announced it has signed a Heads of Agreement (HoA) with the Australian Government for the supply of 51 million doses of the University of Queensland’s (UQ) COVID-19 vaccine candidate (V451), and a separate HoA with AstraZeneca to manufacture the Oxford University candidate (AZD1222), should clinical trials of both prove successful.

This news release is intended for medical, pharmaceutical industry and business media

Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19

Safeguarding our people and communities remains our top priority.

This news release is intended for medical and pharmaceutical trade media and financial media only